RxDoctor Payments Data

Angela Acree

Family · Cadiz, KYNPI 1487324836

Payments from drug & device makers

$4,351in general payments, 2019–2025

Across 237 payments — averaging $18.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$698
  • Johnson & Johnson$698
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$672
  • E.r. Squibb & Sons, L.L.C.$541
  • Bayer$383
  • Merck$271
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$4,26698%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,351 in reported general payments places this provider in the 90th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$51,076
Medicare patients
399
Services billed
843

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban248$240,506
EntrestoSacubitril/Valsartan214$216,407
FarxigaDapagliflozin Propanediol106$82,407
XareltoRivaroxaban83$78,786
JardianceEmpagliflozin66$46,810
Repatha SureclickEvolocumab67$43,675
NexlizetBempedoic Acid/Ezetimibe13$11,933
BrilintaTicagrelor18$10,070
Praluent PenAlirocumab12$5,901
Metoprolol Succinate379$4,157
Rosuvastatin Calcium197$2,376
Ranolazine ErRanolazine24$2,335
Ezetimibe31$1,854
Prasugrel Hcl22$1,767
Atorvastatin Calcium160$1,743

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$240,506248 claims
NovartisEntresto$698$216,407214 claims
AstraZenecaFarxiga, Brilinta$195$92,477124 claims
Johnson & JohnsonXarelto$698$78,78683 claims
Boehringer IngelheimJardiance$149$46,81066 claims
Esperion Therapeutics, Inc.Nexlizet$16$11,93313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,374 family providers in Kentucky.

Other family in Cadiz

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →